This document provides an interim guide on the novel coronavirus (2019-nCoV) that was first identified in Wuhan, China in late 2019. It discusses coronaviruses in general and the epidemiology, transmission, incubation period, clinical features, treatment, and case definitions for 2019-nCoV. Guidelines are provided on infection prevention and control, surveillance, laboratory diagnosis, management, reporting, and travel recommendations. The document aims to guide healthcare professionals in understanding and responding to the emerging 2019-nCoV outbreak.
In light of the rise in MERS CoV cases in the Middle East the Yale-Tulane ESF-8 Planning and Response Program has produced this special report. It was compiled entirely from open source materials. Please feel free to forward the report to anyone who might be interested.
In light of the rise in MERS CoV cases in the Middle East the Yale-Tulane ESF-8 Planning and Response Program has produced this special report. It was compiled entirely from open source materials. Please feel free to forward the report to anyone who might be interested.
Taklimat berkenaan MERS-COV (Middle East Respiratory Syndrome-Corona Virus) - 12 Julai 2013
Virus ini mula tersebar di Arab Saudi, dan perhatian lebih perlu diberikan kepada jemaah-jemaah yang baru pulang dari Umrah di Makkah & Madinah, Arab Saudi.
Middle East Respiratory Syndrome (MERS) adalah salah satu penyakit new emergence dengan potensi pandemi. Globalisasi menjadi salah satu bahasan menarik yang melingkupi penelitian dan pengetahuan tentang MERS dan dampaknya bagi populasi manusia. Presentasi ini dibawakan di depan mahasiswa Akademi Keperawatan Panti Rapih, Sabtu, 7 Juni 2014, sebagai pengantar kegiatan praktek klinik.
Taklimat berkenaan MERS-COV (Middle East Respiratory Syndrome-Corona Virus) - 12 Julai 2013
Virus ini mula tersebar di Arab Saudi, dan perhatian lebih perlu diberikan kepada jemaah-jemaah yang baru pulang dari Umrah di Makkah & Madinah, Arab Saudi.
Middle East Respiratory Syndrome (MERS) adalah salah satu penyakit new emergence dengan potensi pandemi. Globalisasi menjadi salah satu bahasan menarik yang melingkupi penelitian dan pengetahuan tentang MERS dan dampaknya bagi populasi manusia. Presentasi ini dibawakan di depan mahasiswa Akademi Keperawatan Panti Rapih, Sabtu, 7 Juni 2014, sebagai pengantar kegiatan praktek klinik.
This document provides interim guidance for healthcare facilities (e.g., hospitals, long-term care and outpatient facilities, and other settings where healthcare is provided) and will be updated as needed.
Corna virus detail And corona virus in pakistanEmaan Uppal
The 2019–20 coronavirus pandemic is a pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in Wuhan, Hubei, China in December 2019Avoiding close contact with sick individuals; frequently washing hands with soap and water; not touching the eyes, nose, or mouth with unwashed hands; and practicing good respiratory hygiene.
PREVENTION OF CORONA VIRUS INFECTION AMONG HEALTH WORKERS & PATIENTSSANJAY SIR
This presentation is for health care workers & patients to limit the transmission of corona virus infections. it also helps educator of medical, nursing & paramedics to teach their students about control & prevention strategies. it also create awareness among HCWs & common people.
Advice on the use of masks in the community, during
home care and in health care settings in the context of
the novel coronavirus (2019-nCoV) outbreak
Interim guidance
29 January 2020
MR. MOHAMMAD TALAL AL JOHANY
RESPIRATORY THERAPIST
Meqaat Hospital Madina
POST TEST
https://forms.gle/apSH6sR5mRTwRvjJ6
https://youtube.com/channel/UCUlJw6wef_dhQi3TXNTkn6g
OVID-19 Management experience
What we learned from bedside experience in COVID-19 treatment
Dr. Essam A. Salem, ICU Registrar, Meeqat GENERAL.HOSPITAL, Head OF ICU Unit Meeqat General Hospital
Hassan Mohamed Ali
Associate professor of anesthesia and pain management, Anesthesia department, Cairo University.
MB.B.ch, M Sc, M.D, FCAI, DESA
Meeqat General Hospital, Madinah Munawarah
Biological screening of herbal drugs: Introduction and Need for
Phyto-Pharmacological Screening, New Strategies for evaluating
Natural Products, In vitro evaluation techniques for Antioxidants, Antimicrobial and Anticancer drugs. In vivo evaluation techniques
for Anti-inflammatory, Antiulcer, Anticancer, Wound healing, Antidiabetic, Hepatoprotective, Cardio protective, Diuretics and
Antifertility, Toxicity studies as per OECD guidelines
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
2024.06.01 Introducing a competency framework for languag learning materials ...Sandy Millin
http://sandymillin.wordpress.com/iateflwebinar2024
Published classroom materials form the basis of syllabuses, drive teacher professional development, and have a potentially huge influence on learners, teachers and education systems. All teachers also create their own materials, whether a few sentences on a blackboard, a highly-structured fully-realised online course, or anything in between. Despite this, the knowledge and skills needed to create effective language learning materials are rarely part of teacher training, and are mostly learnt by trial and error.
Knowledge and skills frameworks, generally called competency frameworks, for ELT teachers, trainers and managers have existed for a few years now. However, until I created one for my MA dissertation, there wasn’t one drawing together what we need to know and do to be able to effectively produce language learning materials.
This webinar will introduce you to my framework, highlighting the key competencies I identified from my research. It will also show how anybody involved in language teaching (any language, not just English!), teacher training, managing schools or developing language learning materials can benefit from using the framework.
Macroeconomics- Movie Location
This will be used as part of your Personal Professional Portfolio once graded.
Objective:
Prepare a presentation or a paper using research, basic comparative analysis, data organization and application of economic information. You will make an informed assessment of an economic climate outside of the United States to accomplish an entertainment industry objective.
Introduction to AI for Nonprofits with Tapp NetworkTechSoup
Dive into the world of AI! Experts Jon Hill and Tareq Monaur will guide you through AI's role in enhancing nonprofit websites and basic marketing strategies, making it easy to understand and apply.
Synthetic Fiber Construction in lab .pptxPavel ( NSTU)
Synthetic fiber production is a fascinating and complex field that blends chemistry, engineering, and environmental science. By understanding these aspects, students can gain a comprehensive view of synthetic fiber production, its impact on society and the environment, and the potential for future innovations. Synthetic fibers play a crucial role in modern society, impacting various aspects of daily life, industry, and the environment. ynthetic fibers are integral to modern life, offering a range of benefits from cost-effectiveness and versatility to innovative applications and performance characteristics. While they pose environmental challenges, ongoing research and development aim to create more sustainable and eco-friendly alternatives. Understanding the importance of synthetic fibers helps in appreciating their role in the economy, industry, and daily life, while also emphasizing the need for sustainable practices and innovation.
Safalta Digital marketing institute in Noida, provide complete applications that encompass a huge range of virtual advertising and marketing additives, which includes search engine optimization, virtual communication advertising, pay-per-click on marketing, content material advertising, internet analytics, and greater. These university courses are designed for students who possess a comprehensive understanding of virtual marketing strategies and attributes.Safalta Digital Marketing Institute in Noida is a first choice for young individuals or students who are looking to start their careers in the field of digital advertising. The institute gives specialized courses designed and certification.
for beginners, providing thorough training in areas such as SEO, digital communication marketing, and PPC training in Noida. After finishing the program, students receive the certifications recognised by top different universitie, setting a strong foundation for a successful career in digital marketing.
Acetabularia Information For Class 9 .docxvaibhavrinwa19
Acetabularia acetabulum is a single-celled green alga that in its vegetative state is morphologically differentiated into a basal rhizoid and an axially elongated stalk, which bears whorls of branching hairs. The single diploid nucleus resides in the rhizoid.
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
Model Attribute Check Company Auto PropertyCeline George
In Odoo, the multi-company feature allows you to manage multiple companies within a single Odoo database instance. Each company can have its own configurations while still sharing common resources such as products, customers, and suppliers.
Normal Labour/ Stages of Labour/ Mechanism of LabourWasim Ak
Normal labor is also termed spontaneous labor, defined as the natural physiological process through which the fetus, placenta, and membranes are expelled from the uterus through the birth canal at term (37 to 42 weeks
Normal Labour/ Stages of Labour/ Mechanism of Labour
Interim guide to novel coronavirus infection 2019 n cov
1. Interim Guide to Novel
Coronavirus Infection 2019-
nCoV
Dr. Moh’d Alamin Almahdi
Infection Control Unit
Meeqat General Hospital Complex
2. Coronaviruses (CoV)
Coronaviruses (CoV) are a large family of viruses
that cause illnesses ranging from the common cold
to more severe diseases such as
Middle East Respiratory Syndrome (MERS-
CoV)2012 and
Severe Acute Respiratory Syndrome (SARS-
CoV).2003
A novel coronavirus (2019-nCoV)
3. Epidemiology
Novel (new) Coronavirus (2019-2019-nCoV) is a
new strain of coronavirus that was first identified in
a cluster of pneumonia cases in Wuhan City, Hubei
Province of China.
Most of the cases have had exposure to a large
seafood and animal market.
4.
5.
6. Mode of transmission
The mode(s) of transmission of the 2019-
nCoV are currently unknown. Available
information suggests that the 2019-nCoV is
zoonotic and causes infections in humans
through contact with infected animals.
Current data does suggest sustained human-
to-human transmission.
11. Clinical Feature
Most of the cases have shown
respiratory symptoms, fever, shortness
of breath and pneumonia.
12.
13. Treatment
Currently, there is no known treatment
or vaccine available for either people or
animals. Intensive supportive care with
the treatment of symptoms is the main
approach to manage the infection in
people.
14. WHO Clinical management
1. Triage: recognize and sort patients with SARI
2. Immediate implementation of appropriate infection prevention and control
(IPC) measures
3. Early supportive therapy and monitoring
4. Collection of specimens for laboratory diagnosis
5. Management of hypoxemic respiratory failure and acute respiratory
distress syndrome (ARDS)
6. Management of septic shock
7. Prevention of complications
8. Specific anti-nCoV treatments ( Nelfinavir protease inhibitor use HIV
&SARS before was tried)
15. Surveillance Case Definition
Suspected 2019-nCoV is defined as:
A person with acute respiratory illness (fever with
cough and/or shortness of breath) AND any of the
following:
1. A history of travel to China in the 14 days prior to
symptom onset.
2. A close physical contact* in the past 14 days with
a confirmed case of 2019-nCoV infection
16. Sever Acute Respiratory illness (SARI*) and testing for the
common infectious etiologies** were not revealing
SARI: An Acute respiratory illness with history of fever or measured
temperature ≥38 C° and cough; onset within the last ~10 days; and
requiring hospitalization.
**Examples of common infectious etiologies include Streptococcus
pneumoniae, Haemophilus influenzae type B, Legionella pneumophila,
other recognized primary bacterial pneumonias, influenza viruses, and
respiratory syncytial virus
17. Close contact is defined as:
● Health care associated exposure, including providing direct
care for 2019-nCoV patients, working with health care workers
infected with 2019-nCoV, visiting patients or staying in the
same close environment of a 2019-nCoV patient.
● Working together in close proximity or sharing the same
classroom environment with a with 2019-nCoV patient
● Traveling together with 2019-nCoV patient in any kind of
conveyance
● Living in the same household as a 2019-nCoV patient
18. Confirmed 2019-nCoV is defined as:
A Confirmed case is defined as a
suspected case with laboratory
confirmation of 2019-nCoV infection
(see below).
19. Laboratory diagnosis:
At this stage, the laboratory testing for 2019-
nCoV is performed at the national public
health lab ONLY.
Testing is performed to confirm a clinically
suspected case and to screen contacts.
Interim guidance on laboratory testing
issued by WHO is accessible at:
20.
The principles of infection prevention and control strategies
with health care with suspected 2019-nCoV are:
1. Application of Standard Precautions for all patients.
2. Early recognition and source control.
3. Implementation of additional empiric precautions (droplet and
contact and whenever applicable airborne precautions) for suspected
cases.
4. Administrative controls.
5. Environmental and engineering controls.
4. INFECTION PREVENTION AND
CONTROL (IPC)
21. 4.1 Early recognition and source control.
•Encourage HCWs to have a high level of clinical suspicion.
•Activation of respiratory triage (see Appendix 4).
•Post signage reminding symptomatic patients to alert HCWs.
•Promotion of respiratory hygiene/ cough etiquette is an important
preventative measure.
•Suspected 2019-nCoV patients should be placed in an area separate
from other patients, and additional Infection Prevention and Control
IPC (droplet and contact) precautions should be promptly
implemented
22. Application of Standard Precautions for all
patients
- Standard Precautions include:
• Correct and consistent use of available PPE and appropriate hand hygiene.
• Perform hand hygiene before and after all patient contact, and after contact with
respiratory secretions.
• PPE effectiveness depends on adequate and regular supplies.
• Adequate staff training and specifically appropriate human behavior.
• Ensure that environmental cleaning and disinfection procedures are followed
consistently and correctly. Thorough cleaning of environmental surfaces with
water and detergent and applying commonly used hospital level disinfectants
(such as sodium hypochlorite) is an effective and sufficient procedure.
• Manage laundry, food service utensils and medical waste in accordance with safe
routine procedures.
• Prevention of needle-stick or sharps injury
23. Ensure the following respiratory hygiene
measures
• Offer a medical /surgical mask for suspected 2019-
nCoV infection for those who can tolerate it.
• Cover nose and mouth during coughing or sneezing
with tissue or flexed elbow for others.
24. 4.3.1 Contact and Droplet precautions for
suspected 2019-nCoV infection
:
In addition to Standard Precautions, all individuals, including family members, visitors and
HCWs should apply Contact and Droplet precautions.
− Place patients in adequately ventilated single rooms.
− When single rooms are not available, cohort patients suspected of 2019-nCoV infection
together (Place patient beds at least 1 meter apart, when possible, cohort HCWs to
exclusively care for cases to reduce the risk of spreading transmission due to inadvertent
infection control breaches).
− Use a medical mask with an eye/facial protection (i.e. goggles or a face shield).
− Use gloves and a clean, non-sterile, long-sleeved fluid resistant gown.
− Use either single use disposable equipment or dedicated equipment (e.g. stethoscopes,
blood pressure cuffs and thermometers). If equipment needs to be shared among patients,
clean and disinfect between each patient use (e.g. ethyl alcohol 70%).
25. − Refrain from touching eyes, nose or mouth with potentially contaminated hands.
− Avoid the movement and transport of patients out of the room or area unless medically necessary.
− Use designated portable X-ray equipment and/or other important diagnostic equipment.
− If transport is required, use pre-determined transport routes to minimize exposures to staff, other patients
and visitors and apply medical mask to patient.
− Ensure that HCWs who are transporting patients wear appropriate PPE as described in this section and
perform hand hygiene.
− Notify the receiving area of necessary precautions as soon as possible before the patient’s arrival.
− Routinely clean and disinfect patient-contact surfaces.
− Limit the number of HCWs, family members and visitors in contact with a patient with suspected 2019-nCoV
infection.
− Maintain a record of all persons entering the patient’s room including all staff and visitors.
26.
27.
28. .3.2 Airborne precautions for aerosol-
generating procedures for suspected
2019-nCoV infection:
4.3.2 Airborne precautions for aerosol-generating procedures for
suspected 2019-nCoV infection:
Some aerosol generating procedures have been associated with increased risk
of transmission of coronaviruses (SARS-CoV and MERS-CoV) such as tracheal
intubation, non-invasive ventilation, tracheotomy, cardiopulmonary resuscitation,
manual ventilation before intubation and bronchoscopy. HCWs performing
aerosol-generating procedures should note the following:
− Use a fit tested particulate respirator (certified N95).
− Always perform the seal-check when putting on a disposable particulate
respirator (certified N95), always perform the seal-check.
− HCW that all available types of (N95) are not fit to him should be avoided from
29. aerosol-generating procedures or use PAPR.
− Facial hair (beard) prevents proper respirator fit; either avoid aerosol-generating
procedures or use PAPR.
− Use eye protection (i.e. goggles or a face shield).
− Clean, non-sterile, long-sleeved gown and gloves, if gowns are not fluid
resistant, use a waterproof apron for procedures with expected high fluid
volumes that might penetrate the gown.
− Perform procedures in negative pressure rooms with at least 12 air changes per
hour (ACH) and controlled direction of air flow when using mechanical
ventilation.
− Limit the number of persons present in the room to the absolute minimum
required for the patient’s care and support
30.
31. 4.5 Environmental and engineering
controls
− Basic health-care facility infrastructures.
− Ensuring adequate environmental ventilation.
− Adequate environmental cleaning in all areas within a health-care facility.
− Terminal room cleaning at the time of discharge or transfer of patients.
− Physical separation of at least 1-meter distance should be maintained between
each suspect patient and others.
32. Infection control in Healthcare Facilities:
The mode of transmission of 2019-nCoV remains unknown.
In general, the following are recommended:
1. Perform hand hygiene.
2. Visual triage at the entry point of the healthcare facility, for early identification
of all patients with acute respiratory illness
3. Practice contact and droplet precautions while handling 2019-nCoV patient
(suspected/ confirmed), or any related specimens
4. Practice additional precautions for aerosol-generating procedures; wear a fit-
tested N95 mask, eye protection (i.e. goggles or a face shield), gloves and
impermeable apron.
For further guidance, Infection control guidelines applied to MERS shall be
consulted until further notice. The guidelines are available at:
33. Sample collection and transport
It is advised that lower respiratory specimens such as sputum,
endotracheal aspirate, or bronchoalveolar lavage be used when
possible. If patients do not have signs or symptoms of lower respiratory
tract infection or lower tract specimens are not possible or clinically
indicated, nasopharyngeal specimens should be collected (similar to
MERS sample collection).
For assistance on sample transport, call the courier at 8006149999.
For further guidance, please consult the Middle East Respiratory
Syndrome; guidelines for healthcare professionals (Appendix E
Guidelines for MERS-CoV Sample Collection, Packaging and Shipping)
available at:
34. Measures at Points of Entry (PoE):
Health control centers at PoE are required to
visually screen travelers arriving (directly or
indirectly) from China and refer suspected cases (as
defined above) immediately to the regional public
health department to take necessary action.
The World Health Organization does not
recommend any additional health measures for
travelers to and from the China. In the event that
symptoms of a respiratory infection appear
35. Measures at Points of Entry (PoE):
before, during or after travel, the traveler is advised to seek medical care while
sharing travel-related information with the medical service provider.
In order to ensure its ability to deal with suspected cases, it is required of all
health control centers in the PoE assure the following:
1. Policies, procedures and supplies (including personal protection devices) and
workers trained to assess and deal with suspected cases
2. Means for the exchange of information between the PoE operators and the
health control centers in the ports, and between the health control centers in
the ports and the program of the International Health Regulations at the
Ministry.
3. Existing coordination to transfer suspected cases to appropriate health
facilities for evaluation, diagnosis and treatment provision.
4. A functional public health emergency plan for the PoE.
36. 5. Procedures and supplies needed to disinfect and sterilize sites and tools that
are expected to be contaminated during the management of suspected cases
among travelers.
6. Health awareness facilities suitable for travelers, transport operators and
operators working at the port.
7. In the event of a notification of a suspected case traveling on a ship or a
plane, the operator of the means of transportation should provide the required
information in accordance with the maritime health declaration (annex 8 of the
International Health Regulations) or the general declaration of aircraft (annex 9
of the International Health Regulations ). The passenger identification form
should be completed when there is a suspected case on the plane, and include
contact information with the passenger, in accordance with the operational
manuals of the International Air Transport Organization.
37. Reporting and Response
2019-2019-nCoV is an emerging pathogen and
suspected cases must be reported
immediately through:
1. By calling 1937 to report a notifiable infectious
disease AND
2. Through the Health Electronic Surveillance
Network (HESN) under ”acute respiratory illness-
unspecified”
38. Tips for travelers heading to areas where
the 2019-nCoV was reported:
1. Avoid contact with animals (live or dead), animal products or visiting
animal markets.
2. Avoid contact with people with respiratory symptoms.
3. If symptoms of a respiratory infection appear, you should:
a. Stay at home and avoid mixing with others.
b. Request health care, by contacting the health service by phone and
provide them with travel history.
c. Doi not traveling while having symptoms.
d. Cover the mouth and nose with a tissue when coughing or sneezing.
e. Clean hands by washing them for at least 20 seconds with soap and
water, or with alcohol sterilizers.
39. Novel Coronavirus (2019nCoV) Form
Date of initial notification: _____dd/_____mm/_______yyyy
Animal Exposure:
Did the patient have direct/ indirect contact with any animals within the last 14 days?
Yes No Unknown
If yes, please specify and describe the contact (when/where/extent)
Did the patient visit any of the following locations where animals may be present within the last 14
day?
Yes No Unknown
If yes, check all that apply: Farm Petting zoo Agricultural event Live
animal market Slaughterhouse Pet store
Other:________________
Please describe (when/where/extent):
Did the patient has any other occupation that regularly deals with animal?
Yes, specify___________ No Unknown
Note:
APPENDIX 1
Novel Coronavirus (2019nCoV) Form
Date of initial notification: _____dd/_____mm/_______yyyy
Notification
Name of who
completed the form
Contact
number
Date Email
Hospital Name City
At the time of this report, is the case? Confirmed Suspected
Case under investigation Not a case
Patient Information
Full name Date of Birth
_____dd/_____mm/_______yyyy
Identification number: Marital status
Occupation HCW
Non-
HCW_________
Sex Male Female
Phone Number Age
Address House No.:___________ Street name:________ District name:_____
City:________ Province/Region:_____
Education
Clinical Information
Date of symptoms onset _____/_____/_______
Symptoms Yes No Symptoms Yes No
Fever ≥38º Nausea
History of fever (not
measured).
Vomiting
Sore throat Headache
Runny nose Muscle pain
Cough Joint pain
Shortness of breath Diarrhea
Other (specify):
Hospitalization Information
Is/was the patient hospitalized?
Yes, Date of admission ____/_____/______ No
40. List of patient’s contacts
Name of contact Relation to
patient
Last contact date City Sex Phone
____/___/____
Male
Female
____/___/_____
Male
Female
____/___/_____
Male
Female
____/___/____
Male
Female
____/___/____
Male
Female
____/___/____
Male
Female
____/___/____
Male
Female
____/___/____
Male
Female
____/___/____
Male
Female
____/___/____
Male
Female
For follow up of contacts, use the contact tracking form to collect additional information.
APPENDIX 3
Contact Tracing Form
Novel Coronavirus
Name of the contact: ___________________ ID/ Iqama number: ____________________
Age: ________ Nationality: _________________ Phone #:_____________________
Daily Contact Follow-Up Form
1 Day after last exposure
________/_____/________
2 Day after last exposure
________/_____/________
3 Day after last exposure
________/_____/________
4 Day after last exposure
________/_____/________
5 Day after last exposure
_______/_____/________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
6 Day after last exposure
________/_____/________
7 Day after last exposure
________/_____/________
8 Day after last exposure
________/_____/________
9 Day after last exposure
________/_____/________
10 Day after last exposure
________/_____/________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
11 Day after last exposure
________/_____/________
12 Day after last exposure
________/_____/________
13 Day after last exposure
________/_____/________
14 Day after last exposure
________/_____/________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
No symptoms
Fever_____ F
Shortness of breath
Sore throat
Cough
Headache
Muscle/joint pain
Diarrhea _____ times/day
Vomiting/nausea
Runny nose
Others_______________
Note
Region: _____________ Public Health Investigator: ________________________________
APPENDIX 4
41. Visual Triage Checklist Visual Triage Checklist for Acute Respiratory Illness
Date: Time MRN:
Points
(adults)
Score
A. Clinical symptom/sign
Fever >/= 37.8 1
Cough (New or worsening) 1
Shortness of breath (New or worsening) 1
Sore throat and/or runny nose 1
B. Risk of exposure to 2019- nCoV
A history of travel to China in the last 14
days prior to symptom onset
5
Total Score
* Patient or household
A SCORE ≥ 6, PLACE PATIENT IN AN ISOLATION ROOM AND INFORM MD FOR
ASSESSMENT
2019-nCoV TESTING SHOULD BE DONE ONLY ACCORDING TO CASE DEFINITION
Staff name: _____________________ ID number: __________________